Developer docs
API playgroundTry for free, no card

Search company profiles

Define Ventures

Full company profile

uuid00002r1

Namestring
Define Ventures
Legal namestring
Define Ventures Management, LLC
Websiteurl
definevc.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Define Ventures is a privately held, early-stage venture capital firm headquartered in Silicon Valley (San Francisco) that invests exclusively in digital health and health tech companies from incubation through Series B. The firm manages approximately $800 million in assets under management across six funds, with Fund II closed at $200 million in January 2021 and Fund III plus an Opportunities Fund closed at $460 million in April 2023. Define Ventures was founded and is led by Lynne Chou O'Keefe (Founder & Managing Partner), a former Kleiner Perkins Senior Partner in Healthcare Venture who partnered on Livongo (NYSE: LVGO, acquired by Teladoc for $18.5B). The firm's portfolio spans roughly 28 named companies across consumer health (Hims & Hers NYSE: HIMS, FOLX Health, Tia, Found), payer/provider workflow (Cohere Health, Centivo, Concert Health, DexCare), AI/clinical workflow (Luminai, Layer Health, Hyro, Foundation Health), specialty virtual care (9amHealth, Story Health), and pharma/clinical trials (Verana Health, Lightship, Crescendo, Double Blind Bio), with reported cumulative exit value of approximately $23 billion.

Define Ventures generates revenue through classic venture capital fund economics — management fees on committed capital and carried interest on fund profits — and supplements this with the Define Digital logged-in founder resource platform, a published insights/research function (including the 'House of Healthcare' AI investment framework and an AI Pharma C-Suite Report), and annual proprietary events (Founders Summit, AI + Healthcare Summit, JPM Payer/Provider Forums). The firm's value proposition to portfolio founders centers on enterprise healthcare coalition access (72% of partner companies have customers from Define's network of large health systems, payers, employers, and life sciences companies), senior talent placement at two of three partner companies, and follow-on capital sourcing (approximately $1.6 billion raised by founders since initial investment). The legal entity is Define Ventures Management, LLC, an independently owned firm with no parent company.

The firm's competitive positioning rests on a curated senior team and advisor bench that uniquely blends healthcare operators and AI/technology leaders: Venture Partners include Bruce Broussard (former Humana CEO), Frank Williams (former Evolent Health CEO), and Carolyn Magill (former Aetion CEO); advisors include Toby Cosgrove (former Cleveland Clinic CEO), Peter Fine (former Banner Health CEO), Jia Li (former Global Head R&D, Google Cloud AI), Dr. Nigam Shah (Chief Data Scientist, Stanford Health Care), Ashley Yuki Alexander (OpenAI VP Healthcare), Brook Byers (Kleiner Perkins Senior Partner Emeritus), and Beth Bierbower (former Humana Segment President). Distribution to enterprise healthcare buyers is facilitated by direct relationships with Humana, Intermountain Health, Cleveland Clinic, Hackensack Meridian Health, Sutter Health, and Banner Health.

Short descriptiontext

Define Ventures is a privately held, early-stage digital health venture capital firm managing approximately $800 million across six funds, investing from incubation through Series B in category-defining health tech companies and pairing capital with deep healthcare operator and enterprise buyer coalition access.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
early-stage venture capital, digital health investing, health tech venture capital, venture fund management, healthcare AI investments
Industry1 code
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Private Equity (Digital Health)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Venture Capital Fund Management
TypeSubscription Recurring
Description

Define Ventures generates revenue through classic venture capital fund economics: it raises capital from Limited Partners (LPs) into multi-fund vehicles (6 funds, $800 million AUM) and invests across stages (Incubation, Seed, Series A, Series B). Revenue is derived from management fees on committed capital and carried interest on fund profits. The firm has helped its founders raise $1.6 billion (also cited as $1.5 billion) in follow-on capital since initial investment.

definevc.com
2Capital Gains from Exits
TypeLicensing Royalties
Description

Define's portfolio has generated $23 billion in exit value cumulatively, including high-profile exits such as Hims & Hers (NYSE: HIMS) and Livongo (NYSE: LVGO, acquired by Teladoc). Realized exits generate carried interest distributions and reputational capital that fuels future fundraises.

definevc.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details2 tiers
1Fund III & Opportunities Fund (~$460M raised April 2023)
ModelOther
Notes

Fund III raise of $460 million announced April 18, 2023; predecessor Fund II raised $200 million in January 2021. Combined with earlier vehicles, total AUM is approximately $800 million across 6 funds. Pricing (management fee, carry) not publicly disclosed.

definevc.com
2Fund II ($200M, 2021) and earlier vehicles
ModelOther
Notes

Fund II of $200 million raised in January 2021 per Business Insider coverage cited on Define's news page. Specific fund terms not publicly disclosed.

definevc.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Define Digital
Description

Define Ventures' resources platform custom-crafted to support founders' journeys from the earliest stages to impactful scale.

definevc.com
Core offering1 text field

Define Ventures is an early-stage venture capital firm that raises capital from Limited Partners into multi-fund vehicles and invests in digital health and health tech startups from the Incubation stage through Series B. The firm pairs capital with operator-led company-building support, enterprise GTM introductions to a coalition of large health systems, health plans, employers, and life sciences companies, senior talent and board placement, and a proprietary founder resource platform (Define Digital). Core fund vehicles total approximately $800M in AUM across six funds as of April 2023.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • $800 million AUM across 6 funds
+11 more records
Product overview1 text field

Define Ventures operates as a single unified venture capital fund platform rather than a traditional software product company. Its core offering is a multi-stage digital health venture capital fund (6 funds, ~$800M AUM per the About Us page) that invests in early-stage health tech companies from Incubation through Series B, supported by a dedicated founder-resources platform called Define Digital (a logged-in portal at /log-in) and a published Insights, News & Events research publication that includes market thesis content such as the 'House of Healthcare' AI framework and the Pharma C-Suite AI Report. The 'products' listed in this array therefore describe Define Ventures' fund vehicles, founder platform, research publication, and community events rather than a SaaS product portfolio.

Product and service5 records
1Define Ventures Funds (multi-fund venture capital platform)
CategoryVenture Capital Fund Management
Description

Multi-stage venture capital fund platform that invests in early-stage digital health and health tech companies from Incubation through Series B, managing approximately $800 million in AUM across 6 funds (including Fund II of $200M raised January 2021 and Fund III plus an Opportunities Fund of $460M raised April 2023). Capital is deployed through direct investments and syndicated rounds, with revenue derived from management fees on committed capital and carried interest on fund profits.

2Define Digital Founder Resource Platform
CategoryPortfolio Support Platform
Description

Proprietary logged-in resource platform custom-crafted to support Define Ventures' portfolio founders from the earliest stages through impactful scale. Founders authenticate via email/password to access proprietary resources.

3Define Ventures Insights & Research Publication
CategoryMarket Research & Thought Leadership
Description

Long-form insights and research publication from Define Ventures covering Company Building, Announcements, People Matters, and Market Insights categories. Includes proprietary market research reports such as the AI Pharma C-Suite Report and the 'House of Healthcare' AI investing thesis.

4Define Ventures AI + Healthcare Summit and Founders Summit
CategoryEvents and Community Programs
Description

Annual proprietary invite-only summits (AI + Healthcare Summit held May 1, 2025 with OpenAI co-founder & president Greg Brockman as speaker; Founders Summit held annually in 2022, 2023, 2024, and 2025) that bring together the portfolio founder community, C-suite executives, and ecosystem partners for sourcing, community building, and brand.

5Inside the C-Suite Pharma AI Report
CategoryMarket Research Report
Description

Proprietary research report published by Define Ventures based on research with executives from 16 of the top 20 pharma companies, Big Tech firms (AWS, NVIDIA, Oracle Health & Life Sciences), and venture-backed companies (Tempus AI, Datavant). Available as a downloadable PDF gated lead-capture asset.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Define Ventures co-incubated Cohere Health with Humana in 2019. Cohere Health has since expanded from automating prior authorization to becoming a clinical intelligence platform serving multiple U.S. payers. Per Define's AI thesis, Cohere processes more than 12 million prior authorization requests annually for over 660,000 providers nationwide. Humana remains a deeply embedded strategic partner across the Define portfolio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures maintains deep institutional ties with Kleiner Perkins. Founder Lynne Chou O'Keefe is a former Senior Partner in Healthcare Venture at Kleiner Perkins (where she partnered with companies such as Livongo). Fund Advisor Brook Byers is Senior Partner Emeritus at Kleiner Perkins. Communications Advisor Amanda Duckworth is former Partner and CMO at Kleiner Perkins. Multiple Kleiner Perkins portfolio CEOs (e.g., Jim Pursley of Hinge Health/Livongo) serve as advisors. Kleiner Perkins' logo appears on Define's site as a 'leader from industry pioneers'.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Healthcare Advisor A.G. Breitenstein is Founder & Former CEO of FOLX Health and a former Co-founder & Partner at Optum Ventures. She was honored in Rock Health's Top 50 in Digital Healthcare (May 6, 2024) during her tenure as a Define advisor.

4Brook Byers (Kleiner Perkins Senior Partner)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures Fund Advisor. Brook Byers has been a venture capital investor since 1972; formed the first life sciences practice group in VC in 1984 at Kleiner Perkins. Led Kleiner Perkins to become premier in life sciences, healthcare, digital health, and biotechnology. Has collaborated with Founder Lynne Chou O'Keefe for 12+ years. Sits on boards including Verana Health, Arsenal Bio, Octave Bio, Newsela. Stanford Center for BioDesign board, UCSF Medical Center Lifetime Board Member.

definevc.com
5Toby Cosgrove (Former Cleveland Clinic CEO)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures Healthcare Advisor. Former CEO and current Executive Advisor of Cleveland Clinic; led the $8B organization from 2004-2017, ranked the #2 hospital in America (U.S. News). Board member of Cleveland Clinic Abu Dhabi, American Well, Hims & Hers (a Define portfolio company), and View. Holds 30 patents for medical innovations. Member, National Academy of Medicine.

definevc.com
6Jia Li (Former Global Head R&D, Google Cloud AI)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures AI Advisor. Co-founder of LiveX AI; Founding Global Head of R&D at Google Cloud AI; former Head of Research at Snap; IEEE Fellow. Adjunct Professor at Stanford School of Medicine; co-taught inaugural Generative AI and Medicine course at Stanford. PhD from Stanford CS.

definevc.com
7Dr. Nigam Shah (Chief Data Scientist, Stanford Health Care)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures AI Advisor (joined August 2025). Professor of Medicine at Stanford University; Chief Data Scientist for Stanford Health Care. 350+ publications, h-index 88, 38,000+ citations. Co-founder of the Coalition for Health AI. Boards include Prealize Health and Atropos Health. Co-founder of three companies that collectively raised over $100M.

definevc.com
8Beth Bierbower (Former Segment President, Humana)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures Healthcare Advisor. 30+ years in health insurance including leadership of Humana's Group and Specialty Segment generating $7B+ revenue covering 11M members; led development of Humana's largest TRICARE contract valued at $40B. Currently serves on Boards of Option Care Health, BlueSprig, Paradigm Corp., Quest Analytics.

definevc.com
9Jim Pursley (President, Hinge Health)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures Commercial Advisor. President of Hinge Health (NYSE: HNGE). Former Chief Commercial Officer for Livongo Health, where he helped take it public in 2019 and was part of the $18.5B Teladoc acquisition. Previously held leadership roles at GE Healthcare and Intel-GE Care Innovations.

definevc.com
10Peter Fine (Former CEO, Banner Health)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Define Ventures Healthcare Advisor (joined May 2025). Former President & CEO of Banner Health for 21 years; Banner operates 33 hospitals in 6 states with $14B+ revenue. Honored in Modern Healthcare's 100 Most Influential People in Healthcare for 11 consecutive years (2011-2023).

definevc.com
11Seth Cohen (President, Cedar)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Commercial Advisor. President and Board member of Cedar, the leading provider of patient financial solutions managing 30M+ patient interactions annually across 55+ clients. Previously co-founded OODA Health (acquired by Cedar in 2021); early employee at Castlight Health. Baker Scholar MBA from Harvard.

definevc.com
12Ashley Yuki Alexander (VP Healthcare, OpenAI; former Co-Head Product, Instagram)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Former Consumer Advisor. Currently VP of Product, Healthcare at OpenAI; formerly Co-Head of Product at Instagram; 10-year Meta veteran who built Instagram's ads business from the ground up. Dual degree in CS from UPenn and BS Economics/Marketing/Healthcare Management from Wharton.

definevc.com
13Bangaly Kaba (Director of Product, YouTube; former Head of Growth, Instagram)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Consumer Advisor. Product Management executive at YouTube managing Creator Monetization; previously Head of Growth at Instagram where he helped scale IG from 450M to 1B+ monthly actives in 2.5 years; former VP Product at Instacart; active angel investor and board member.

definevc.com
14Debby Meredith (Tech Advisor; ex-Netscape/AOL SVP)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Tech Advisor with 25+ years working with engineering and product teams. Former VenturePartner at Mohr Davidow Ventures. Former SVP Strategic Technologies & Products at Netscape/AOL, VP Engineering at Collabra Software and Slate Corporation. Trustee of the Computer History Museum. MS CS from Stanford, BS CS/Math from University of Michigan.

definevc.com
15Amanda Duckworth (Former Partner & CMO, Kleiner Perkins)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Communications Advisor. Reputation management expert; led Kleiner Perkins' communications team during the Ellen Pao trial. Founded and led the San Francisco office of Brunswick Group. Executive Partner at Next Horizon Capital. LL.B. from University of Wales.

definevc.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Define Ventures Healthcare Advisor A.G. Breitenstein was a Co-founder & Partner at Optum Ventures prior to founding FOLX Health. Bridges Define's network with Optum/UnitedHealth ecosystem of payers and providers.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Humana is both the co-incubator of Cohere Health (with Define in 2019) and a customer of Cohere Health's clinical intelligence platform. Humana is repeatedly cited on Define's 'leaders from industry pioneers' logo strip and as a featured strategic enterprise healthcare partner. Cohere Health, under Define's partnership, serves multiple payers across the U.S.

Strategic tierMinorTypeOthers
Description

Livongo Health (NYSE: LVGO) is referenced throughout Define's content as a heritage company Founder Lynne Chou O'Keefe partnered on while Senior Partner at Kleiner Perkins. Livongo was acquired by Teladoc Health for $18.5B in 2020. Jim Pursley (Define Commercial Advisor) was Livongo's CCO.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Andreessen Horowitz operates a dedicated bio/health fund investing across digital health, biotech, and healthcare AI. Like Define, it leads early-stage rounds in health tech founders but at significantly larger AUM and broader stage range.

TypeDirect peer
Description

General Catalyst runs a Health Assurance thesis investing across stages in healthcare transformation. Define co-invests with General Catalyst (e.g., Luminai Series B) and competes on similar enterprise-led digital health opportunities.

TypeDirect peer
Description

Oak HC/FT is a healthcare- and fintech-focused venture firm investing across stages. Like Define, it concentrates exclusively on healthcare with deep operator networks and a focus on services + technology convergence.

TypeBroad incumbent
Description

Norwest is a large multi-stage venture firm with a dedicated healthcare practice. It co-invested with Define in Hyro's growth round and competes for similar enterprise healthcare AI deals, though it operates as a generalist.

TypeBroad incumbent
Description

Bessemer is a multi-stage venture firm with a long-standing healthcare practice. Define Principal Chuka Esiobu previously worked at Bessemer, illustrating talent and deal-flow overlap in early-stage health tech.

TypeBroad incumbent
Description

KKR's Health Care Strategic Growth strategy invests across healthcare services, tech, and life sciences with a growth-equity orientation. It competes with Define on later-stage health tech deals where strategic capital matters.

TypeDirect peer
Description

Maverick Ventures is an early-stage venture firm with a dedicated health practice investing in seed and Series A digital health. Direct comparable to Define in stage focus and check size.

TypeEmerging player
Description

Optum Ventures is the corporate venture arm of Optum/UnitedHealth Group investing in early-stage health tech. Define advisor A.G. Breitenstein co-founded Optum Ventures, creating deep network ties; it competes on enterprise-pilot-driven health tech deals.

TypeDirect peer
Description

Flare Capital is an early-stage healthcare technology venture firm focused on digital health, health IT, and services. Direct comparable to Define on stage focus and enterprise-pilot-driven thesis.

TypeDirect peer
Description

Health Velocity Capital invests in healthcare software, services, and technology-enabled businesses across stages. Direct comparable to Define in healthcare-only mandate and operator-led value-add model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers30 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment57 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Define Ventures

Venture Capital / Private Equity (Digital Health)definevc.com

Define Ventures is a privately held, early-stage digital health venture capital firm managing approximately $800 million across six funds, investing from incubation through Series B in category-defining health tech companies and pairing capital with deep healthcare operator and enterprise buyer coalition access.

What Define Ventures does

Define Ventures is a privately held, early-stage venture capital firm headquartered in Silicon Valley (San Francisco) that invests exclusively in digital health and health tech companies from incubation through Series B. The firm manages approximately $800 million in assets under management across six funds, with Fund II closed at $200 million in January 2021 and Fund III plus an Opportunities Fund closed at $460 million in April 2023. Define Ventures was founded and is led by Lynne Chou O'Keefe (Founder & Managing Partner), a former Kleiner Perkins Senior Partner in Healthcare Venture who partnered on Livongo (NYSE: LVGO, acquired by Teladoc for $18.5B). The firm's portfolio spans roughly 28 named companies across consumer health (Hims & Hers NYSE: HIMS, FOLX Health, Tia, Found), payer/provider workflow (Cohere Health, Centivo, Concert Health, DexCare), AI/clinical workflow (Luminai, Layer Health, Hyro, Foundation Health), specialty virtual care (9amHealth, Story Health), and pharma/clinical trials (Verana Health, Lightship, Crescendo, Double Blind Bio), with reported cumulative exit value of approximately $23 billion.

Define Ventures generates revenue through classic venture capital fund economics — management fees on committed capital and carried interest on fund profits — and supplements this with the Define Digital logged-in founder resource platform, a published insights/research function (including the 'House of Healthcare' AI investment framework and an AI Pharma C-Suite Report), and annual proprietary events (Founders Summit, AI + Healthcare Summit, JPM Payer/Provider Forums). The firm's value proposition to portfolio founders centers on enterprise healthcare coalition access (72% of partner companies have customers from Define's network of large health systems, payers, employers, and life sciences companies), senior talent placement at two of three partner companies, and follow-on capital sourcing (approximately $1.6 billion raised by founders since initial investment). The legal entity is Define Ventures Management, LLC, an independently owned firm with no parent company.

The firm's competitive positioning rests on a curated senior team and advisor bench that uniquely blends healthcare operators and AI/technology leaders: Venture Partners include Bruce Broussard (former Humana CEO), Frank Williams (former Evolent Health CEO), and Carolyn Magill (former Aetion CEO); advisors include Toby Cosgrove (former Cleveland Clinic CEO), Peter Fine (former Banner Health CEO), Jia Li (former Global Head R&D, Google Cloud AI), Dr. Nigam Shah (Chief Data Scientist, Stanford Health Care), Ashley Yuki Alexander (OpenAI VP Healthcare), Brook Byers (Kleiner Perkins Senior Partner Emeritus), and Beth Bierbower (former Humana Segment President). Distribution to enterprise healthcare buyers is facilitated by direct relationships with Humana, Intermountain Health, Cleveland Clinic, Hackensack Meridian Health, Sutter Health, and Banner Health.

Define Ventures firmographics

Firmographics
Name
Define Ventures
Legal name
Define Ventures Management, LLC
Website
https://definevc.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Define Ventures is a privately held, early-stage digital health venture capital firm managing approximately $800 million across six funds, investing from incubation through Series B in category-defining health tech companies and pairing capital with deep healthcare operator and enterprise buyer coalition access.
Ownership category
akta.pro rank

Define Ventures industry classification

Industry
Product category
Venture Capital / Private Equity (Digital Health)
NAICS
Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Early-stage venture capital
  • Digital health investing
  • Health tech venture capital
  • Venture fund management
  • Healthcare AI investments

Where Define Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Define Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Venture Capital Fund Management: Define Ventures generates revenue through classic venture capital fund economics: it raises capital from Limited Partners (LPs) into multi-fund vehicles (6 funds, $800 million AUM) and invests across stages (Incubation, Seed, Series A, Series B). Revenue is derived from management fees on committed capital and carried interest on fund profits. The firm has helped its founders raise $1.6 billion (also cited as $1.5 billion) in follow-on capital since initial investment.
  2. Capital Gains from Exits: Define's portfolio has generated $23 billion in exit value cumulatively, including high-profile exits such as Hims & Hers (NYSE: HIMS) and Livongo (NYSE: LVGO, acquired by Teladoc). Realized exits generate carried interest distributions and reputational capital that fuels future fundraises.

Pricing tiers

ModelBillingPrice
Other—Fund III & Opportunities Fund (~$460M raised April 2023)
Other—Fund II ($200M, 2021) and earlier vehicles

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Define Ventures product offering

Product offering

Core offering

Define Ventures is an early-stage venture capital firm that raises capital from Limited Partners into multi-fund vehicles and invests in digital health and health tech startups from the Incubation stage through Series B. The firm pairs capital with operator-led company-building support, enterprise GTM introductions to a coalition of large health systems, health plans, employers, and life sciences companies, senior talent and board placement, and a proprietary founder resource platform (Define Digital). Core fund vehicles total approximately $800M in AUM across six funds as of April 2023.

Product overview

Define Ventures operates as a single unified venture capital fund platform rather than a traditional software product company. Its core offering is a multi-stage digital health venture capital fund (6 funds, ~$800M AUM per the About Us page) that invests in early-stage health tech companies from Incubation through Series B, supported by a dedicated founder-resources platform called Define Digital (a logged-in portal at /log-in) and a published Insights, News & Events research publication that includes market thesis content such as the 'House of Healthcare' AI framework and the Pharma C-Suite AI Report. The 'products' listed in this array therefore describe Define Ventures' fund vehicles, founder platform, research publication, and community events rather than a SaaS product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • Define Digital: Define Ventures' resources platform custom-crafted to support founders' journeys from the earliest stages to impactful scale.

Products and services

  • Define Ventures Funds (multi-fund venture capital platform) Multi-stage venture capital fund platform that invests in early-stage digital health and health tech companies from Incubation through Series B, managing approximately $800 million in AUM across 6 funds (including Fund II of $200M raised January 2021 and Fund III plus an Opportunities Fund of $460M raised April 2023). Capital is deployed through direct investments and syndicated rounds, with revenue derived from management fees on committed capital and carried interest on fund profits.
  • Define Digital Founder Resource Platform Proprietary logged-in resource platform custom-crafted to support Define Ventures' portfolio founders from the earliest stages through impactful scale. Founders authenticate via email/password to access proprietary resources.
  • Define Ventures Insights & Research Publication Long-form insights and research publication from Define Ventures covering Company Building, Announcements, People Matters, and Market Insights categories. Includes proprietary market research reports such as the AI Pharma C-Suite Report and the 'House of Healthcare' AI investing thesis.
  • Define Ventures AI + Healthcare Summit and Founders Summit Annual proprietary invite-only summits (AI + Healthcare Summit held May 1, 2025 with OpenAI co-founder & president Greg Brockman as speaker; Founders Summit held annually in 2022, 2023, 2024, and 2025) that bring together the portfolio founder community, C-suite executives, and ecosystem partners for sourcing, community building, and brand.
  • Inside the C-Suite Pharma AI Report Proprietary research report published by Define Ventures based on research with executives from 16 of the top 20 pharma companies, Big Tech firms (AWS, NVIDIA, Oracle Health & Life Sciences), and venture-backed companies (Tempus AI, Datavant). Available as a downloadable PDF gated lead-capture asset.

Quantifiable outcome

  • $800 million AUM across 6 funds
  • +11 more outcomes

Companies that use Define Ventures

Customer profile

Named customers30 records

Segments3 records

Ideal customer profiles3 records

Define Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Define Ventures partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered flagship, core and minor.

  • HumanaflagshipStrategic or Co-development Partner · 1 January 2019Define Ventures co-incubated Cohere Health with Humana in 2019. Cohere Health has since expanded from automating prior authorization to becoming a clinical intelligence platform serving multiple U.S. payers. Per Define's AI thesis, Cohere processes more than 12 million prior authorization requests annually for over 660,000 providers nationwide. Humana remains a deeply embedded strategic partner across the Define portfolio.
  • Kleiner PerkinscoreStrategic or Co-development PartnerDefine Ventures maintains deep institutional ties with Kleiner Perkins. Founder Lynne Chou O'Keefe is a former Senior Partner in Healthcare Venture at Kleiner Perkins (where she partnered with companies such as Livongo). Fund Advisor Brook Byers is Senior Partner Emeritus at Kleiner Perkins. Communications Advisor Amanda Duckworth is former Partner and CMO at Kleiner Perkins. Multiple Kleiner Perkins portfolio CEOs (e.g., Jim Pursley of Hinge Health/Livongo) serve as advisors. Kleiner Perkins' logo appears on Define's site as a 'leader from industry pioneers'.
  • FOLX Health (via advisor A.G. Breitenstein)coreStrategic or Co-development PartnerDefine Ventures Healthcare Advisor A.G. Breitenstein is Founder & Former CEO of FOLX Health and a former Co-founder & Partner at Optum Ventures. She was honored in Rock Health's Top 50 in Digital Healthcare (May 6, 2024) during her tenure as a Define advisor.
  • Brook Byers (Kleiner Perkins Senior Partner)flagshipStrategic or Co-development PartnerDefine Ventures Fund Advisor. Brook Byers has been a venture capital investor since 1972; formed the first life sciences practice group in VC in 1984 at Kleiner Perkins. Led Kleiner Perkins to become premier in life sciences, healthcare, digital health, and biotechnology. Has collaborated with Founder Lynne Chou O'Keefe for 12+ years. Sits on boards including Verana Health, Arsenal Bio, Octave Bio, Newsela. Stanford Center for BioDesign board, UCSF Medical Center Lifetime Board Member.
  • Toby Cosgrove (Former Cleveland Clinic CEO)flagshipStrategic or Co-development PartnerDefine Ventures Healthcare Advisor. Former CEO and current Executive Advisor of Cleveland Clinic; led the $8B organization from 2004-2017, ranked the #2 hospital in America (U.S. News). Board member of Cleveland Clinic Abu Dhabi, American Well, Hims & Hers (a Define portfolio company), and View. Holds 30 patents for medical innovations. Member, National Academy of Medicine.
  • Jia Li (Former Global Head R&D, Google Cloud AI)flagshipStrategic or Co-development PartnerDefine Ventures AI Advisor. Co-founder of LiveX AI; Founding Global Head of R&D at Google Cloud AI; former Head of Research at Snap; IEEE Fellow. Adjunct Professor at Stanford School of Medicine; co-taught inaugural Generative AI and Medicine course at Stanford. PhD from Stanford CS.
  • Dr. Nigam Shah (Chief Data Scientist, Stanford Health Care)flagshipStrategic or Co-development PartnerDefine Ventures AI Advisor (joined August 2025). Professor of Medicine at Stanford University; Chief Data Scientist for Stanford Health Care. 350+ publications, h-index 88, 38,000+ citations. Co-founder of the Coalition for Health AI. Boards include Prealize Health and Atropos Health. Co-founder of three companies that collectively raised over $100M.
  • Beth Bierbower (Former Segment President, Humana)flagshipStrategic or Co-development PartnerDefine Ventures Healthcare Advisor. 30+ years in health insurance including leadership of Humana's Group and Specialty Segment generating $7B+ revenue covering 11M members; led development of Humana's largest TRICARE contract valued at $40B. Currently serves on Boards of Option Care Health, BlueSprig, Paradigm Corp., Quest Analytics.
  • Jim Pursley (President, Hinge Health)flagshipStrategic or Co-development PartnerDefine Ventures Commercial Advisor. President of Hinge Health (NYSE: HNGE). Former Chief Commercial Officer for Livongo Health, where he helped take it public in 2019 and was part of the $18.5B Teladoc acquisition. Previously held leadership roles at GE Healthcare and Intel-GE Care Innovations.
  • Peter Fine (Former CEO, Banner Health)flagshipStrategic or Co-development PartnerDefine Ventures Healthcare Advisor (joined May 2025). Former President & CEO of Banner Health for 21 years; Banner operates 33 hospitals in 6 states with $14B+ revenue. Honored in Modern Healthcare's 100 Most Influential People in Healthcare for 11 consecutive years (2011-2023).
  • Seth Cohen (President, Cedar)coreStrategic or Co-development PartnerDefine Ventures Commercial Advisor. President and Board member of Cedar, the leading provider of patient financial solutions managing 30M+ patient interactions annually across 55+ clients. Previously co-founded OODA Health (acquired by Cedar in 2021); early employee at Castlight Health. Baker Scholar MBA from Harvard.
  • Ashley Yuki Alexander (VP Healthcare, OpenAI; former Co-Head Product, Instagram)coreStrategic or Co-development PartnerDefine Ventures Former Consumer Advisor. Currently VP of Product, Healthcare at OpenAI; formerly Co-Head of Product at Instagram; 10-year Meta veteran who built Instagram's ads business from the ground up. Dual degree in CS from UPenn and BS Economics/Marketing/Healthcare Management from Wharton.
  • Bangaly Kaba (Director of Product, YouTube; former Head of Growth, Instagram)coreStrategic or Co-development PartnerDefine Ventures Consumer Advisor. Product Management executive at YouTube managing Creator Monetization; previously Head of Growth at Instagram where he helped scale IG from 450M to 1B+ monthly actives in 2.5 years; former VP Product at Instacart; active angel investor and board member.
  • Debby Meredith (Tech Advisor; ex-Netscape/AOL SVP)coreStrategic or Co-development PartnerDefine Ventures Tech Advisor with 25+ years working with engineering and product teams. Former VenturePartner at Mohr Davidow Ventures. Former SVP Strategic Technologies & Products at Netscape/AOL, VP Engineering at Collabra Software and Slate Corporation. Trustee of the Computer History Museum. MS CS from Stanford, BS CS/Math from University of Michigan.
  • Amanda Duckworth (Former Partner & CMO, Kleiner Perkins)coreStrategic or Co-development PartnerDefine Ventures Communications Advisor. Reputation management expert; led Kleiner Perkins' communications team during the Ellen Pao trial. Founded and led the San Francisco office of Brunswick Group. Executive Partner at Next Horizon Capital. LL.B. from University of Wales.
  • Optum Ventures (via advisor A.G. Breitenstein)coreStrategic or Co-development PartnerDefine Ventures Healthcare Advisor A.G. Breitenstein was a Co-founder & Partner at Optum Ventures prior to founding FOLX Health. Bridges Define's network with Optum/UnitedHealth ecosystem of payers and providers.
  • Humana (commercial customer of Cohere Health)flagshipStrategic or Co-development PartnerHumana is both the co-incubator of Cohere Health (with Define in 2019) and a customer of Cohere Health's clinical intelligence platform. Humana is repeatedly cited on Define's 'leaders from industry pioneers' logo strip and as a featured strategic enterprise healthcare partner. Cohere Health, under Define's partnership, serves multiple payers across the U.S.
  • Livongo (exited portfolio of Founder's prior fund at Kleiner Perkins)minorOthersLivongo Health (NYSE: LVGO) is referenced throughout Define's content as a heritage company Founder Lynne Chou O'Keefe partnered on while Senior Partner at Kleiner Perkins. Livongo was acquired by Teladoc Health for $18.5B in 2020. Jim Pursley (Define Commercial Advisor) was Livongo's CCO.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Define Ventures competitors and assessment

Company assessment

Direct peers

  • Andreessen Horowitz (a16z) Bio/Health: Andreessen Horowitz operates a dedicated bio/health fund investing across digital health, biotech, and healthcare AI. Like Define, it leads early-stage rounds in health tech founders but at significantly larger AUM and broader stage range.
  • General Catalyst: General Catalyst runs a Health Assurance thesis investing across stages in healthcare transformation. Define co-invests with General Catalyst (e.g., Luminai Series B) and competes on similar enterprise-led digital health opportunities.
  • Oak HC/FT: Oak HC/FT is a healthcare- and fintech-focused venture firm investing across stages. Like Define, it concentrates exclusively on healthcare with deep operator networks and a focus on services + technology convergence.
  • Maverick Ventures: Maverick Ventures is an early-stage venture firm with a dedicated health practice investing in seed and Series A digital health. Direct comparable to Define in stage focus and check size.
  • Flare Capital Partners: Flare Capital is an early-stage healthcare technology venture firm focused on digital health, health IT, and services. Direct comparable to Define on stage focus and enterprise-pilot-driven thesis.
  • Health Velocity Capital: Health Velocity Capital invests in healthcare software, services, and technology-enabled businesses across stages. Direct comparable to Define in healthcare-only mandate and operator-led value-add model.

Broad incumbents

  • Norwest Venture Partners: Norwest is a large multi-stage venture firm with a dedicated healthcare practice. It co-invested with Define in Hyro's growth round and competes for similar enterprise healthcare AI deals, though it operates as a generalist.
  • Bessemer Venture Partners: Bessemer is a multi-stage venture firm with a long-standing healthcare practice. Define Principal Chuka Esiobu previously worked at Bessemer, illustrating talent and deal-flow overlap in early-stage health tech.
  • KKR Health Care Strategic Growth: KKR's Health Care Strategic Growth strategy invests across healthcare services, tech, and life sciences with a growth-equity orientation. It competes with Define on later-stage health tech deals where strategic capital matters.

Emerging players

  • Optum Ventures: Optum Ventures is the corporate venture arm of Optum/UnitedHealth Group investing in early-stage health tech. Define advisor A.G. Breitenstein co-founded Optum Ventures, creating deep network ties; it competes on enterprise-pilot-driven health tech deals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Define Ventures social profiles

Digital presence

Define Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Define Ventures leadership team

Management profile

Number of profiles

Profiles12 records

Define Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Define Ventures M&A and investment

M&A and investment

M&A

Investments57 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Define Ventures

What does Define Ventures do?

Define Ventures is an early-stage venture capital firm that raises capital from Limited Partners into multi-fund vehicles and invests in digital health and health tech startups from the Incubation stage through Series B. The firm pairs capital with operator-led company-building support, enterprise GTM introductions to a coalition of large health systems, health plans, employers, and life sciences companies, senior talent and board placement, and a proprietary founder resource platform (Define Digital). Core fund vehicles total approximately $800M in AUM across six funds as of April 2023.

Is Define Ventures a public or private company?

Define Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Define Ventures founded?

Define Ventures was founded in 2019. It employs 11 to 50 people.

Where is Define Ventures based?

Define Ventures is headquartered in San Francisco, United States, in the North America region.

How does Define Ventures make money?

Two revenue lines are on record. Venture Capital Fund Management is the primary driver. The others are capital Gains from Exits.

Who are Define Ventures's main competitors?

Direct peers on record are Andreessen Horowitz (a16z) Bio/Health, General Catalyst, Oak HC/FT, Maverick Ventures, Flare Capital Partners and Health Velocity Capital. Broad incumbents are Norwest Venture Partners, Bessemer Venture Partners and KKR Health Care Strategic Growth. Optum Ventures is listed as an emerging player.

Does Define Ventures have an API?

No public API is recorded for Define Ventures.

What industry is Define Ventures in?

Define Ventures's product category is Venture Capital / Private Equity (Digital Health). Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingDefine Ventures invests in WHOOPDefine Ventures invested in WHOOP, an AI-powered health-monitoring company expanding into healthcare. The partnership brings healthcare industry relationships to support WHOOP's transition into preventive medicine.The future of tradingDefine Ventures leads Readily USD 11 million Series A roundDefine Ventures led Readily's $11 million Series A financing, with YC and the California HealthCare Foundation participating. Readily's AI-native compliance platform serves healthcare organizations across 46 states, cutting regulatory analysis time from three weeks to two hours and audits from nine months to three.BeckershospitalreviewYale New Haven Health, Endeavor Health invest in AI coding platformArintra raised $25 million in a Series B round led by Define Ventures, with Yale New Haven Health and Endeavor Health among investors. The AI coding platform now has $51 million in total funding and processes over $5 billion in annual claim value. It will use the funds to expand across health systems and broaden specialty coverage.BioSpaceArintra Raises $25M to Pioneer Revenue Assurance for America’s Health SystemsArintra raised $25 million in a Series B led by Define Ventures, bringing total funding to $51 million. The company's revenue assurance platform processes over $5 billion in annual claim value and has deployed across health systems like UC Davis Health and Rochester Regional Health. The funding will expand enterprise health system coverage and deepen clinical specialty support.WowtaleRNA Foundation model BlankBio, Claude's 'destructive hypothesis' can.San Francisco-based AI biotech startup Blank Bio has developed a foundation model called Ladon, trained on 20 years of bulk RNA sequencing data, which maps biological states to enable researchers to find connections across different experimental contexts without relying on text-based searches. The company integrated Ladon with Anthropic's Claude AI agent via an embedding search MCP, which successfully generated a novel hypothesis about cellular senescence in ME/CFS patients — a mechanism independently evaluated as promising by domain experts. Blank Bio raised $7.2 million in an oversubscribed seed round in May, with participation from Y Combinator, SignalFire, Define Ventures, and others, and simultaneously formed a strategic partnership with PacBio for precision oncology RNA foundation model development.FinSMEsBlank Bio Raises $7.2M in Seed FundingBlank Bio, a San Francisco AI lab training foundation models for RNA, raised $7.2M in seed funding from Define Ventures, Leonis Capital, and others. The company will use the funds for model development, collaborations with pharma and diagnostic firms, and new long-read RNA-seq datasets for biomarkers and diagnostics.Venture Capital Access OnlineBlank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision OncologyBlank Bio closed a $7.2 million seed financing and a strategic collaboration with PacBio to advance RNA foundation models for precision oncology. The collaboration will generate long-read bulk RNA-seq data from up to 100 patient tumor samples to train and evaluate the models. Proceeds will support model development, expanded partnerships, and new datasets.PharmiWeb.comPharmiWeb.com – Thank youPharmiWeb.com is closing after 28 years, having operated since 1998. The company thanks members, advertisers, partners, and readers for their contributions. It notes the site was among the first in the dot-com era.BioSpaceBlank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision OncologyBlank Bio closed a $7.2 million seed financing and a strategic collaboration with PacBio to advance RNA foundation models for precision oncology. The collaboration will generate long-read bulk RNA-seq data from up to 100 patient tumor samples to train and evaluate the models. Proceeds will support model development, expanded partnerships, and new datasets.Vestbee9amHealth raises $26M to expand AI-driven chronic care platform beyond cardiometabolic health9amHealth raised $26 million in Series B funding led by Define Ventures to expand its AI-driven virtual specialty care platform beyond cardiometabolic conditions. The California-based firm will use the funds to scale clinical operations and technology for additional high-cost chronic conditions, aiming to reduce employer healthcare costs.